Daily Stock Analysis, ALIM, Alimera Sciences Inc, priceseries

Alimera Sciences Inc. Daily Stock Analysis
Stock Information
Open
1.18
Close
1.28
High
1.30
Low
1.17
Previous Close
1.19
Daily Price Gain
0.09
YTD High
1.36
YTD High Date
Jan 8, 2018
YTD Low
1.03
YTD Low Date
Feb 9, 2018
YTD Price Change
-0.04
YTD Gain
-3.03%
52 Week High
1.72
52 Week High Date
Mar 16, 2017
52 Week Low
1.03
52 Week Low Date
Feb 9, 2018
52 Week Price Change
0.06
52 Week Gain
4.92%
Company Information
Stock Symbol
ALIM
Exchange
NasdaqGM
Company URL
http://www.alimerasciences.com
Company Phone
6789905740
CEO
Charles Daniel Myers
Headquarters
Georgia
Business Address
6120 WINDWARD PARKWAY, STE 290, ALPHARETTA, GA 30005
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001267602
About

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.